Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003874 · ClinicalTrials.gov registry record · Phase 1
Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Leukemia
A Phase 1 study, sponsored by Fred Hutchinson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00003874: Completed Phase 1 study, sponsored by Fred Hutchinson Cancer Center.
NCT00003874 is a Phase 1 study that has completed, run by Fred Hutchinson Cancer Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003874, a Phase 1 study, has completed, sponsored by Fred Hutchinson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances without harming normal cells. PURPOSE: Phase I/II trial to study the effectiveness of monoclonal antibody therapy in treating patients who have lymphoma or leukemia.
Interventions
- PROCEDURE in vitro-treated peripheral blood stem cell transplantation
- BIOLOGICAL monoclonal antibody CD19
- BIOLOGICAL monoclonal antibody CD20
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-02 |
| Est. Completion | 2001-09 |
| Phase | Phase 1 |
What the finished NCT00003874 record still lists
NCT00003874 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 3 interventions - of which in vitro-treated peripheral blood stem cell transplantation is the first listed.
NCT00003874 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00003874 about?
NCT00003874 is a clinical study titled "Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Leukemia". RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances without harming normal cells. PURPOSE: Phase I/II trial to study the effectiveness of monoclonal antibody therapy in treating patients who have lymphoma or leukemia.
What is the current status of trial NCT00003874?
This trial is currently completed. It is a Phase 1 study. The study started on 1999-02. Estimated completion is 2001-09.
What interventions are being tested in trial NCT00003874?
The interventions under investigation include: in vitro-treated peripheral blood stem cell transplantation (PROCEDURE), monoclonal antibody CD19 (BIOLOGICAL), monoclonal antibody CD20 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003874?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia